Moolec Science (MLEC, Financial) has successfully completed its strategic merger with Bioceres Group, Gentle Technologies, and Nutrecon. This significant merger, initially announced in April 2025 and approved by shareholders in June, strengthens Moolec's position as a leading force in sustainable life sciences and food technology. The deal unifies several sectors, including food ingredients, ag-biologicals, and precision fermentation, enhancing Moolec's capacity to deliver innovative, sustainable solutions.
As part of this transformative transaction, Bioceres Group shareholders exchanged their stakes for approximately 6.9 million shares in Moolec. Additionally, shareholders from Nutrecon and Gentle Technologies received around 0.65 million Moolec shares and 0.5 million private warrants, each warrant carrying a $20.00 strike price. The company will continue under the Moolec Science name, with its securities listed on NASDAQ under the ticker MLEC. The board has also appointed Mr. Alejandro Antalich as the new CEO, guiding Moolec Science into this new phase of growth and innovation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Moolec Science SA (MLEC, Financial) is $30.00 with a high estimate of $30.00 and a low estimate of $30.00. The average target implies an upside of 322.54% from the current price of $7.10. More detailed estimate data can be found on the Moolec Science SA (MLEC) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Moolec Science SA's (MLEC, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
